Prospera Financial Services Inc Invests $245,000 in IQVIA Holdings Inc. (NYSE:IQV)

Prospera Financial Services Inc bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,033 shares of the medical research company’s stock, valued at approximately $245,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Canada Pension Plan Investment Board boosted its holdings in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares during the last quarter. Impax Asset Management Group plc lifted its position in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares in the last quarter. Legal & General Group Plc boosted its stake in IQVIA by 0.8% during the second quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after buying an additional 11,715 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of IQVIA by 5.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock worth $253,125,000 after acquiring an additional 60,827 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IQV. Leerink Partners reissued an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Barclays cut their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, BTIG Research lowered their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Stock Performance

Shares of IQV stock opened at $204.02 on Tuesday. The firm has a 50 day moving average of $221.96 and a two-hundred day moving average of $226.98. The stock has a market capitalization of $37.03 billion, a PE ratio of 26.77, a P/E/G ratio of 2.08 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.